NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Combination Drug Therapy for Patients With Hepatitis C
- Conditions
- Chronic Hepatitis CFibrosisHemolytic Anemia
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 120
- Registration Number
- NCT00001729
- Locations
- 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States
Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants
- Conditions
- Kidney DiseaseGraft Rejection
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2019-12-17
- Target Recruit Count
- 294
- Registration Number
- NCT00001858
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia
- Conditions
- Hodgkin's DiseaseLymphoma, Non-Hodgkin
- Interventions
- Biological: Y-90 Humanized Anti-TacDrug: Calcium-DTPA
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 87
- Registration Number
- NCT00001575
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
p53 Vaccine for Ovarian Cancer
- Conditions
- Ovarian Neoplasm
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00001827
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation
- Conditions
- Graft vs Host DiseaseMultiple Myeloma
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2007-09-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00001561
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Therapy in Lupus Nephropathy
- Conditions
- Nephrotic SyndromeSystemic Lupus Erythematosus
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-04-09
- Target Recruit Count
- 45
- Registration Number
- NCT00001212
- Locations
- 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States
Evaluating Patients With Abnormal Levels of Gastric Acid
- Conditions
- AchlorhydriaGastrinomaZollinger Ellison Syndrome
- Locations
- 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States
Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
- Conditions
- Islet Cell AdenomaNeoplasm MetastasisZollinger Ellison Syndrome
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 999
- Registration Number
- NCT00001165
- Locations
- 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States
Observation of HIV-Infected Children Receiving Protease Inhibitor and Reverse Transcriptase Inhibitor
- Conditions
- HIV Infection
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00001826
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas
- Conditions
- Hodgkin's DiseaseNon Hodgkin's Lymphoma
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 49
- Registration Number
- NCT00001430
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States